MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
27.44
-0.37
-1.33%
Opening 09:43 12/05 EST
OPEN
27.72
PREV CLOSE
27.81
HIGH
27.89
LOW
27.39
VOLUME
29.42K
TURNOVER
--
52 WEEK HIGH
45.30
52 WEEK LOW
25.71
MARKET CAP
5.07B
P/E (TTM)
-21.0764
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LEGN last week (1124-1128)?
Weekly Report · 4d ago
Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
Barchart · 11/27 08:00
H.C. Wainwright says Legend Biotech competition concerns overdone
TipRanks · 11/26 11:20
Buy Rating for Legend Biotech Reaffirmed Due to CARVYKTI’s Strong Market Position and Proven Efficacy
TipRanks · 11/26 11:17
Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?
Seeking Alpha · 11/25 19:38
Interesting LEGN Put And Call Options For January 2026
NASDAQ · 11/24 15:36
Weekly Report: what happened at LEGN last week (1117-1121)?
Weekly Report · 11/24 10:41
Legend Biotech (NasdaqGS:LEGN): Assessing Valuation After Strong Results and New Philadelphia R&D Launch
Simply Wall St · 11/24 09:21
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.